Jackson TL, Soare C, Petrarca C, et al. - Researchers conducted this randomized clinical trial to test the safety and effectiveness of epimacular brachytherapy (EMB) for chronic, active, neovascular age-related macular degeneration (ARMD). This trial was carried out at 24 National Health Service hospitals across the UK. Between November 10, 2009, and January 30, 2012, patients (n = 363) who had neovascular ARMD and received intravitreal ranibizumab were recruited. According to findings, EMB did not lessen the frequency of anti-vascular endothelial growth factor injections and was linked to worse visual acuity at month 24 compared with as-needed ranibizumab monotherapy. Such results do not support the addition of EMB to anti-vascular endothelial growth factor treatment for neovascular ARMD.